ClinicalTrials.gg
CompletedNCT04019704GEMINIUpdated Oct 12, 2022Results posted

A Trial of AXS-05 in Patients With Major Depressive Disorder

A Phase 3 interventional study of AXS-05 and Placebo in Depression and Major Depressive Disorder, sponsored by Axsome Therapeutics, Inc.. Completed at 43 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-10-12.

Sponsored by Axsome Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
327
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,713 studies in Depression with a site in United States — 582 open to participants now, 720 under way, 30 of them phase 3. Depression · United States.

Enrollment
501st of 3,320
327 · median 72
Started
2019
with 183 others
Phase 3
237 of 3,713
19 open now
Registered
2,225th of 3,713
by date

Among the 3,713 studies in Depression with a site in United States, this one is the 501st largest by enrollment of the 3,320 interventional ones that give a count, is one of 184 that started in 2019, is one of 237 in phase 3, and was the 2,225th registered.

Depression

8,595 studies on the registry are indexed under Depression; 1,732 are open to participants now.

Browse Depression studies →

Open to participants now

582 of the 3,713 studies in Depression with a site in United States are open now. Recruiting first, the newest first:

577 more — sign in →

All 582 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,094 Depression studies recruiting now, 472 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 314 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,713 studies in Depression with a site in United States, or all of them as a file.
02

Study summary

A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of AXS-05 in patients with major depressive disorder (MDD).

Read the detailed description

This study will evaluate AXS-05 in a randomized, double-blind, placebo-controlled study in patients with MDD. Eligible patients will be randomized in a 1:1 ratio to treatment with AXS-05 or placebo for 6 weeks.

03

Conditions studied

  • Depression
  • Major Depressive Disorder

Keywords

  • Depressive Disorder
  • Depressive Disorder, Major
  • Bupropion
  • Dextromethorphan
  • MDD
  • Dopamine Reuptake Inhibitor
  • AXS-05
  • NMDA Receptor Antagonist
  • Central Nervous System
  • CNS
  • Sigma-1 Receptor Agonist
  • Nicotinic Acetylcholine Receptor Antagonist
  • Norepinephrine Reuptake Inhibitor
  • Glutamate Modulator
  • Axsome Therapeutics
  • GEMINI
  • Serotonin Reuptake Inhibitor
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Age 18 - 65
  • Currently meets criteria for MDD
  • between 18 and 40 kg/m\^2, inclusive

Key Exclusion Criteria:

  • Suicide risk
  • History of treatment resistance in current depressive episode
  • History of electroconvulsive therapy, vagus nerve stimulation, transcranial magnetic stimulation or any experimental central nervous system treatment during the current episode or in the past 6 months
  • Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
327 participants (actual)

Study arms

  • Experimental
    AXS-05

    AXS-05 (bupropion and dextromethorphan) oral tablets

    Drug: AXS-05

  • Placebo comparator
    Placebo

    Placebo oral tablets to match AXS-05

    Drug: Placebo

Interventions

  • DrugAXS-05

    Oral AXS-05 tablets, taken daily for 6 weeks.

  • DrugPlacebo

    Placebo to match oral AXS-05 tablets, taken daily for 6 weeks.

06

What researchers measure

Primary outcomes

  1. Change in MADRS Total Score From Baseline to Week 6

    The primary objective of the study was to evaluate the efficacy of AXS-05 as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) for change in severity of depressive symptoms from baseline to Week 6. The MADRS is a 10-item scale and items are scored between 0-6 points. For each item, a score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity. A maximum total score is 60 points.

    Time frame: 6 weeks

07

Results

Posted Oct 12, 2022

Participant flow

Participant flow — Overall Study
MilestoneAXS-05Placebo
Started163164
Completed123147
Not completed4017

Outcome measures

PrimaryChange in MADRS Total Score From Baseline to Week 6

The primary objective of the study was to evaluate the efficacy of AXS-05 as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) for change in severity of depressive symptoms from baseline to Week 6. The MADRS is a 10-item scale and items are scored between 0-6 points. For each item, a score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity. A maximum total score is 60 points.

Time frame:
6 weeks
Reported as:
Least squares mean · score on a scale
Change in MADRS Total Score From Baseline to Week 6
score on a scaleAXS-05Placebo
Change in MADRS Total Score From Baseline to Week 615.91 ± 0.92112.04 ± 0.862
Statistical analysis
  • AXS-05 vs Placebo · Mixed Models Analysis · p = 0.002

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) were AEs with an onset date on or after the date of first dose. TEAEs were collected through 30 days after the last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AXS-050/162 (0%)1/162 (0.6%)100/162 (61.7%)
Placebo0/164 (0%)0/164 (0%)74/164 (45.1%)
Most frequent serious events
Most frequent serious events
EventAXS-05Placebo
PancreatitisGastrointestinal disorders1/1620/164
Most frequent other events
Most frequent other events
EventAXS-05Placebo
All Others, occurring in <5% of SubjectsGeneral disorders47/16243/164
DizzinessNervous system disorders26/16210/164
NauseaGastrointestinal disorders21/16214/164
HeadacheNervous system disorders13/1626/164
DiarrheaGastrointestinal disorders11/1625/164
SomnolenceNervous system disorders11/1625/164
Dry mouthGastrointestinal disorders9/1624/164

Baseline characteristics

Participants randomized

Age, Continuous
Age, Continuous(years)AXS-05PlaceboTotal
Mean42.1 ± 12.7141.1 ± 13.7841.6 ± 13.25
Sex: Female, Male
Sex: Female, Male(Participants)AXS-05PlaceboTotal
Female98117215
Male6547112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AXS-05PlaceboTotal
American Indian or Alaska Native112
Asian9817
Native Hawaiian or Other Pacific Islander123
Black or African American6155116
White8892180
More than one race336
Unknown or Not Reported033
08

Study locations

43 sites
  • Clinical Research Site
    Phoenix, Arizona 85012, United States
  • Clinical Research Site
    Phoenix, Arizona 85016, United States
  • Clinical Research Site
    Little Rock, Arkansas 72209, United States
  • Clinical Research Site
    Bellflower, California 90706, United States
  • Clinical Research Site
    Beverly Hills, California 90210, United States
  • Clinical Research Site
    Garden Grove, California 92845, United States
  • Clinical Research Site
    Oakland, California 94607, United States
  • Clinical Research Site
    Oceanside, California 92056, United States
  • Clinical Research Site
    Panorama City, California 91402, United States
  • Clinical Research Site
    Redlands, California 92374, United States
  • Clinical Research Site
    Riverside, California 92506, United States
  • Clinical Research Site
    San Diego, California 92103, United States
  • Clinical Research Site
    Sherman Oaks, California 91403, United States
  • Clinical Research Site
    Upland, California 91786, United States
  • Clinical Research Site
    Coral Springs, Florida 33067, United States
  • Clinical Research Site
    Hollywood, Florida 33024, United States
  • Clinical Research Site
    Jacksonville, Florida 32256, United States
  • Clinical Research Site
    Lauderhill, Florida 33319, United States
  • Clinical Research Site
    North Miami, Florida 33161, United States
  • Clinical Research Site
    Orlando, Florida 32801, United States
  • Clinical Research Site
    Atlanta, Georgia 30328, United States
  • Clinical Research Site
    Boise, Idaho 83704, United States
  • Clinical Research Site
    Chicago, Illinois 60634, United States
  • Clinical Research Site
    Boston, Massachusetts 02131, United States
  • Clinical Research Site
    Las Vegas, Nevada 89102, United States
  • Clinical Research Site
    Berlin, New Jersey 08009, United States
  • Clinical Research Site
    Cherry Hill, New Jersey 08002, United States
  • Clinical Research Site
    Toms River, New Jersey 08755, United States
  • Clinical Research Site
    Jamaica, New York 11432, United States
  • Clinical Research Site
    Rochester, New York 14618, United States
  • Clinical Research Site
    Staten Island, New York 10312, United States
  • Clinical Research Site
    Hickory, North Carolina 28601, United States
  • Clinical Research Site
    Cincinnati, Ohio 45219, United States
  • Clinical Research Site
    Middleburg Heights, Ohio 44130, United States
  • Clinical Research Site
    Oklahoma City, Oklahoma 73112, United States
  • Clinical Research Site
    Media, Pennsylvania 19063, United States
  • Clinical Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Clinical Research Site
    Memphis, Tennessee 38119, United States
  • Clinical Research Site
    Dallas, Texas 75243, United States
  • Clinical Research Site
    Fort Worth, Texas 76104, United States
  • Clinical Research Site
    Houston, Texas 77058, United States
  • Clinical Research Site
    Wichita Falls, Texas 76309, United States
  • Clinical Research Site
    Everett, Washington 98201, United States
09

References and documents

Publications

  • Iosifescu DV, Jones A, O'Gorman C, Streicher C, Feliz S, Fava M, Tabuteau H. Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI). J Clin Psychiatry. 2022 May 30;83(4):21m14345. doi: 10.4088/JCP.21m14345. PubMed 35649167 ↗
  • Dean RL, Hurducas C, Hawton K, Spyridi S, Cowen PJ, Hollingsworth S, Marquardt T, Barnes A, Smith R, McShane R, Turner EH, Cipriani A. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev. 2021 Sep 12;9(9):CD011612. doi: 10.1002/14651858.CD011612.pub3. PubMed 34510411 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Nov 2019, 5 months.

Results were first posted in Oct 2022, 2 years 10 months after primary completion. A results delay was requested in Dec 2020.

Of 81 phase 3 interventional studies under Depression, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2019
First posted
Jul 15, 2019
StartActual
Jun 20, 2019
Primary completionActual
Nov 26, 2019
CompletionActual
Dec 5, 2019
Results delay requested
Dec 7, 2020
Results first posted
Oct 12, 2022
Last update
Oct 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04019704
Responsible party
Sponsor
First posted
Jul 15, 2019
Start date
Jun 20, 2019
Primary completion
Nov 26, 2019
Completion
Dec 5, 2019
Results posted
Oct 12, 2022
Last update
Oct 12, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dextromethorphan/Bupropion Tablet AXS-05

Start the discussion